12 months 24 months 36 months p-value ALT normalization (<40 IU/L) 0.248*  IFN-LdT 59.62 88.28 92.97    LdT 59.1 81.44 84.09 HBV DNA undetectability (<2.7 log copies/ml) 0.112* IFN-LdT 65.38 87.69 95.08    LdT 52.27 76.25 90.95 HBeAg<100 (S/CO) 0.010*，†  IFN-LdT 51.92 87.35 89.46    LdT 22.73 65.25 83.71 HBeAg loss (<1 S/CO) 0.361*  IFN-LdT 21.15 41.81 69.34    LdT 13.64 33.08 54.89 HBeAg seroconversion 0.047*,† IFN-LdT 13.66 36.67 61.55    LdT 18.18 23.49 40.68 HBsAg loss (<0.05 IU/ml) 0.708* IFN-LdT 0 2.22 10.22    LdT 0 2.5 6.93

Table 2: Cumulative Probabilities of Antiviral Response During LdT Treatment. Data are presented in percent. ALT, alanine aminotransferase; HBV, Hepatitis B virus; HBeAg, Hepatitis B e antigen; HBsAg, Hepatitis B surface antigen; IFN, interferon; LdT, telbivudine. *Log-rank (Mantel-cox) chi square test; †p<0.05.